Involving Proteinase Patents (Class 435/23)
-
Publication number: 20150051288Abstract: Disclosed herein are methods and compositions for treating autism. Disclosed herein are methods and compositions for treating an autism spectrum disorder.Type: ApplicationFiled: October 10, 2014Publication date: February 19, 2015Inventors: Paul Talalay, Andrew W. Zimmerman, Kirby D. Smith
-
Publication number: 20150050680Abstract: Providing is a new enzyme assay method for enzymes having a water-insoluble or substantially water-insoluble substrate. In the method for measuring enzymatic activity, a prescribed amount of an enzyme is disposed on a part of the surface of a gel comprising dispersoids, at least some of which are the substrate of the enzyme. Recesses formed in the surface of the gel by the action of the enzyme are measured, and the enzyme activity is calculated on the basis of the measurement results and the amount of the enzyme. The measurement of the recesses formed in the surface of the gel is performed using a method for measuring the shape and the volume of the recesses, a method for measuring changes in the optical transmittance of the gel due to the formation of the recesses, or a method for measuring changes in the optical reflectance of the gel surface due to the formation of the recesses.Type: ApplicationFiled: February 20, 2013Publication date: February 19, 2015Applicants: Japan Agency for Marine-Earth Science and Technology, Kyokuto Pharmaeutical Industrial Co., Ltd.Inventors: Shigeru Deguchi, Mikiko Tsudome, Kazunori Nagaki, Nemuri Todaka, Yasunori Kurosawa
-
Publication number: 20150044715Abstract: Disclosed is a method which enables semiquantitative or quantitative determination of the ratio between cysteine and formylglycine residues in a protein. The method includes (a) a step of labeling the protein (i) with a halogen-substituted carboxylic acid, (ii) with a halogen-substituted carboxylic acid amide, and (iii) with a halogen-substituted carboxylic acid and then with hydrazine, or with a halogen-substituted carboxylic acid and then by oximation, (b) a step of digesting each labeled protein to provide a corresponding mixture of peptide fragments, (c) a step of subjecting each mixture to reverse phase chromatography to separate the peptide fragments from each other to produce a chromatogram, (d) a step of comparing the produced chromatograms with each other to identify the peak corresponding to the peptide fragment that contained a cysteine residue and the peak corresponding to the peptide fragment that contained a formylglycine residue.Type: ApplicationFiled: December 18, 2012Publication date: February 12, 2015Inventor: Tetsuo Yokoyama
-
Publication number: 20150037828Abstract: Aspects of the disclosure include methods for analyzing an analyte composition by mass spectrometry employing a macroporous metal organic polymer matrix. In practicing methods according to certain embodiments an analyte composition is applied to a macroporous metal organic polymer matrix, a voltage is applied to the macroporous metal organic polymer matrix sufficient to produce and expel analyte ions from the macroporous metal organic polymer matrix and the analyte ions are analyzed by mass spectrometry. In other embodiments, a composition having biological macromolecules is applied onto a surface-modified macroporous metal organic polymer matrix and analytes produced by reaction (e.g., enzymatic cleavage of the biological macromolecules) at or near the surface of the macroporous metal organic polymer matrix are measured by mass spectrometry.Type: ApplicationFiled: July 31, 2014Publication date: February 5, 2015Inventors: Maria T. Dulay, Richard N. Zare, Livia Schiavinato Eberlin
-
Publication number: 20150038443Abstract: The present invention provides small molecules useful to affect cancer cells, along with related methods. The present compounds, formulations, kits and methods are useful for a variety of research, diagnostic and therapeutic purposes. STAT3 inhibitors, particularly LLL12, are disclosed. The STAT3 inhibitors are useful to treat breast cancer in general and breast cancer initiating cells in particular.Type: ApplicationFiled: October 16, 2014Publication date: February 5, 2015Applicants: NATIONWIDE CHILDREN'S HOSPITAL, INC., THE OHIO STATE UNIVERSITYInventors: Pui-Kai Li, Chenglong Li, Jiayuh Lin
-
Publication number: 20150037292Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.Type: ApplicationFiled: February 11, 2013Publication date: February 5, 2015Applicant: Orbsen Therapeutics LimitedInventor: Stephen Joseph Elliman
-
Patent number: 8945861Abstract: Methods for producing an isotope-labeled mammalian, including a human, biomolecule, such as polypeptides and proteins, in a cell-free protein synthesis system. A biomolecule standard is produced having at least one isotope different in abundance than that of the naturally occurring isotopes in the biomolecule. Methods for quantifying biomolecules standards expressed using mammalian cell-free extracts are disclosed. Methods for producing such standards, kits, systems and reagents, relating to the use of isotope-labeled biomolecule as quantification standards in mass spectrometric and nuclear magnetic resonance analysis.Type: GrantFiled: August 2, 2012Date of Patent: February 3, 2015Assignee: Pierce Biotechnology, Inc.Inventors: Ryan D. Bomgarden, Eric Leigh Hommema, John Charles Rogers, Penny JoAnn Jensen, Derek Karl Baerenwald
-
Patent number: 8945917Abstract: A novel enhanced surface area conico-cylindrical flask (ES-CCF) providing increased surface area by virtue of its' inner arrangement and useful in routine small-scale studies of bioactives production by any biofilm-forming marine as well as terrestrial microorganisms. Compared to corresponding Erlenmeyer flask of similar volume the ES-CCF provides more than 80% additional surface for biofilm attachment and growth. The ES-CCF does not require steam sterilization and is durable as the device is constructed of polymethyl methacrylate or any other such hydrophobic material and offers possibility of altering the nature of the growth surface (hydrophilic and hydrophobic). The ES-CCF also provides external aeration like a bioreactor, thus increasing the versatility of applications. Further, the device can be operated as a cylindrical flask, that is without the inner arrangement.Type: GrantFiled: May 19, 2011Date of Patent: February 3, 2015Assignee: Counci of Scientific & Industrial Research and School of Environmental StudiesInventors: Sreyashi Sarkar, Debashis Roy, Joydeep Mukherjee
-
Patent number: 8945863Abstract: The present invention relates to a method for measuring the activity of enzymes in a sample which contains at least one enzyme and at least one enzyme inhibitor corresponding to said enzyme, whereby after de-inhibition the activity of the released enzyme is measured in such a way that a substrate is added to the sample and the time course of the concentration of at least one reaction product (cleavage product) is recorded and the enzyme specific substrate has a fluorogenic part which is cleaved in the enzymatic reaction and the fluorescence (measuring parameter) of which can be detected in a wavelength range where the measuring parameter can be assigned unambiguously to the enzyme activity to be measured, whereby the de-inhibition is carried out by immersing a rigid carrier, to which the inhibitor binding substance is bound, into the sample. The present invention relates also to a corresponding device for measuring the activity on enzymes in a sample.Type: GrantFiled: January 8, 2010Date of Patent: February 3, 2015Assignee: Papst Licensing GmbH & Co. KGInventors: Hans Jörg Meier, Hans Werner Hofer
-
Publication number: 20150031872Abstract: The purpose of the present invention is to provide a method for screening anticancer drugs that use novel treatment mechanisms, and an anticancer drug that induces cell death and uses a substance that increases the activity of granzyme M as an active ingredient. This method for screening anticancer drugs comprises: a step for administering test substances to cancer cells; a step for detecting the activity of granzyme M in which cancer cells are expressed, and selecting test substances for which an increase in activity has been verified; and/or a step for detecting the presence or absence of cancer cell death induced by the activation of granzyme M in which cancer cells are expressed, and selecting test substances for which cell death has been verified.Type: ApplicationFiled: March 13, 2013Publication date: January 29, 2015Inventors: Shunichiro Kubota, Motohiko Sato, Liyun Wang
-
Publication number: 20150031064Abstract: Materials and Methods for identifying and measuring pharmacodynamic biomarkers of neuropsychiatric disease (e.g., major depressive disorder), stratifying disease severity, and monitoring a subject's response to treatment are provided.Type: ApplicationFiled: June 9, 2014Publication date: January 29, 2015Inventors: John Bilello, Bo Pi
-
Publication number: 20150031063Abstract: The present invention pertains to a method of detection, by mass spectrometry, of at least one marker of at least one mechanism of resistance to at least one antimicrobial, resistance of at least one microorganism contained in a sample, characterised in that the antimicrobial is a carbapenem, and said resistance markers are proteins or peptides. Preferably, said proteins or peptides are proteins from said microorganism.Type: ApplicationFiled: April 20, 2012Publication date: January 29, 2015Applicant: BIOMERIEUX, INC.Inventors: Yannick Charretier, Jean-Philippe Charrier, Christine Franceschi, Gilles Zambardi, Tiphaine Cecchini, Elodie Degout-Charmette
-
Publication number: 20150031057Abstract: Method for the determination of the renal function wherein the amount of at least one agrin fragment derived by neurotrypsin cleavage of agrin is measured in a sample taken from a patient and the measured amount of the agrin-fragment in the sample is used as indicator for renal function.Type: ApplicationFiled: February 22, 2013Publication date: January 29, 2015Inventors: Stefan Hettwer, Jan Willem Vrijbloed, Dominik Stuebl, Marcel Roos
-
Publication number: 20150031065Abstract: The present invention provides methods for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. The present invention also provides compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).Type: ApplicationFiled: July 25, 2014Publication date: January 29, 2015Inventors: PAUL EDWARD KEARNEY, Kenneth Charles Fang, Xiao-Jun Li, Clive Hayward
-
Publication number: 20150017664Abstract: The present application relates to a composition including gut flora-derived extracellular vesicles, and to an animal disease model using same. In addition, the present application relates to a method for using the gut flora-derived extracellular vesicles to efficiently search for a candidate drug which may prevent or treat diseases that occur due to gut flora-derived extracellular vesicles, and to a vaccine which can efficiently prevent or treat infections caused by gut flora or diseases that occur due to gut flora-derived extracellular vesicles. Further, the development of diagnostic technology to discover, using the gut flora-derived extracellular vesicles of the present application, the etiology of diseases that occur due to gut flora-derived extracellular vesicles, can be achieved.Type: ApplicationFiled: July 2, 2014Publication date: January 15, 2015Inventors: Yoon Keun KIM, Yong Song GHO, Kyoung Su PARK, Bok Sil HONG, Ji Hyun KIM, You Sun KIM, Won Hee LEE, Jung Wook KIM, Dae-Kyum KIM
-
Publication number: 20150017672Abstract: Disclosed herein are novel methods, assays and kits useful for the diagnosis and monitoring of subjects with mucopolysaccharidoses (MPS). The methods, assays and kits are particularly useful for detecting the presence of one or more glycosaminoglycans which correlate to MPS and its severity in a variety of biological samples.Type: ApplicationFiled: February 1, 2013Publication date: January 15, 2015Inventors: Juan Ruiz, Marcia Sellos-Moura, Philip Shi
-
Patent number: 8932826Abstract: The present invention relates to a chromogenic method for simultaneously determining the activity of multiple coagulation proteases or for simultaneously determining the inhibition of multiple coagulation proteases in a single test reaction. For this purpose, use is made of two chromogenic substrates which have different absorption maxima and whose color signals can be separated spectrally.Type: GrantFiled: December 15, 2011Date of Patent: January 13, 2015Assignee: Siemens Healthcare Diagnostics Products GmbHInventor: Norbert Zander
-
Patent number: 8932820Abstract: Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin.Type: GrantFiled: September 13, 2012Date of Patent: January 13, 2015Assignee: Siemens Healthcare Diagnostics Products GmbHInventors: Harald Althaus, Tobias Obser, Juergen Patzke, Reinhard Schneppenheim
-
Publication number: 20150010935Abstract: Embodiments of the present disclosure relate to amino acid, modified amino acid, peptide and protein identification and sequencing, by means of, for example, electronic detection of individual amino acids or small peptides.Type: ApplicationFiled: January 31, 2013Publication date: January 8, 2015Inventors: Stuart Lindsay, Peiming Zhang, Yanan Zhao
-
Publication number: 20150010532Abstract: The invention relates to recombinant nucleic acid and polypeptides encoding collagenase I and collagenase II, methods for the preparation thereof and methods for the use thereof. The invention also encompasses methods related to releasing a composition comprising collagenase prior to therapeutic administration.Type: ApplicationFiled: July 11, 2014Publication date: January 8, 2015Inventor: Wayne K. Herber
-
Publication number: 20150010931Abstract: A cell based assay for detection for protease activity is disclosed. In the assay a cell is engineered to express a protease substrate with at least one label, preferably on its C-terminus. Cleavage of the substrate by the protease that recognizes it results in a C-terminal fragment and a N-terminal fragment, where the fragment having the label is subject to ubiquitin proteasome degradation. The assay measures the disappearance of the label due to degradation of the fragment to which it is attached. A cell free assay is also described for detection of protease activity. In the cell free assay, the protease substrate is expressed in a solution that includes the elements of the ubiquitin proteasome pathway for degradation of the fragment. The assay measures the disappearance of the label attached to the fragment that results from cleavage by the protease.Type: ApplicationFiled: June 13, 2011Publication date: January 8, 2015Applicant: Synaptic Research, LLCInventors: George A. Oyler, Yien Che Tsai
-
Publication number: 20150010925Abstract: A method for measuring expression of autoregulatory molecules within living cells is provided. An autoregulatory molecule and marker construct is expressed in vivo, where the marker is cleaved from the construct during translation. The method comprises the expression of a construct having an autoregulatory molecule bound to a measurable expression marker by a cleavable linker. The cleavable linker is the substrate of a protease, which acts on its substrate in vivo during translation. Cleavage during translation, allows the autoregulatory molecule to fold normally as it would in its native form. The measurable marker is released and available for detection upon cleavage by the protease. As a result, the concentration of the measurable marker is directly related to the level of expression of the autoregulatory molecule.Type: ApplicationFiled: June 27, 2014Publication date: January 8, 2015Inventors: Jie Xiao, Zachary Hensel
-
Patent number: 8927220Abstract: A protein used as a biomarker for diagnosing IgA nephropathy and TGBM (thin-glomerular-basement-membrane) using urine through a target proteomics method. A diagnosis biomarker protein and a kit for diagnosing IgA nephropathy and TGBM and predicting progress of the nephropathy in advance using the protein are provided. The degree of the progression of the disease can be grasped by detecting IgA nephropathy and TGBM, enabling early diagnosis and confirming progress from the patient's urine. In addition, a monoclonal antibody produced based on the diagnosis biomarker protein can be used for an immunoassay kit (ELISA, antibody coated tube test, lateral-flow test, potable biosensor). The monoclonal antibody is used in early diagnosis and progression detection of IgA nephropathy and development of a novel drug for the purpose of treatment.Type: GrantFiled: September 30, 2009Date of Patent: January 6, 2015Assignee: Kyungpook National University Industry-Academic Cooperation FoundationInventors: Moon Chang Baek, Pyong Gon Moon, Yong Lim Kim
-
Patent number: 8927290Abstract: Provided herein are compositions comprising native and denatured human leukocyte antigens (HLA) and methods of making said compositions. Also provided herein are methods and kits for the detection of antibodies to native HLAs.Type: GrantFiled: February 16, 2011Date of Patent: January 6, 2015Assignee: One Lambda, Inc.Inventors: Adam Idica, Chun-Tsan Deng, Paul I. Terasaki
-
Publication number: 20150005182Abstract: This patent application discloses and describes proteins found to be differentially expressed between primary tumor breast cancer cells that did not give rise to recurrent breast cancer disease after initial diagnosis and primary breast cancer cells that did give rise to recurrent breast cancer disease after initial diagnosis. These proteins can be used either individually or in specific combinations in diagnostic and prognostic protein assays on various biological samples from breast cancer patients to indicate the likelihood that a breast cancer patient's cancer will recur after initial diagnosis and treatment. Determination of differential expression of these proteins can also be useful for indicating additional therapies to combat the likelihood of recurrent breast cancer. The full length intact proteins can be assayed or peptides derived from these proteins can be assayed as reporters for these proteins.Type: ApplicationFiled: July 1, 2013Publication date: January 1, 2015Applicant: EXPRESSION PATHOLOGY, INC.Inventors: David Krizman, Marlene M. Darfler, Thomas P. Conrads, Brian L. Hood
-
Publication number: 20150005183Abstract: This patent application discloses and describes proteins found to be differentially expressed between primary tumor breast cancer cells histologicaly defined as early stage (stage 0) breast cancer and primary breast cancer cells histologicaly defined as late stage (stage 3) breast cancer. These proteins can be used either individually or in specific combinations in diagnostic and prognostic protein assays on various biological samples from breast cancer patients to indicate the that a breast cancer patient's cancer is in an early, non-aggressive stage or in a late, aggressive stage. Determination of differential expression of these proteins can also be useful for indicating additional therapies to combat the aggressiveness of late stage breast cancer. The full length intact proteins can be assayed or peptides derived from these proteins can be assayed as reporters for these proteins.Type: ApplicationFiled: July 1, 2013Publication date: January 1, 2015Applicant: EXPRESSION PATHOLOGY, INC.Inventors: David Krizman, Marlene M. Darfler, Thomas P. Conrads, Brian L. Hood
-
Publication number: 20150005193Abstract: Disclosed herein are “equipment-free” flow-through assay devices based on patterned porous media, methods of making same, and methods of using same. The porous, hydrophilic media are patterned with hydrophobic barriers for performing assays on liquids.Type: ApplicationFiled: June 20, 2014Publication date: January 1, 2015Inventors: Scott Thomas Phillips, Gregory Gerald Lewis, Jessica Sloane Robbins
-
Patent number: 8921063Abstract: Provided herein are methods for detecting endotoxin or Gram negative bacteria in a sample. Kits for detecting endotoxin or Gram negative bacteria in a sample are provided.Type: GrantFiled: February 28, 2012Date of Patent: December 30, 2014Assignee: BioDtech, Inc.Inventors: Michael G. Pepe, Milton Keith Champion
-
Patent number: 8916357Abstract: Methods for identifying a compound capable of interacting with a Receptor Tyrosine Kinase (RTK) including providing a device capable of measuring cell-substrate impedance, adding test cells expressing a RTK to the device, measuring first impedances, adding a compound to at least one compound well and adding a vehicle control to at least one control well, measuring second impedances of the compound well and the control well, determining the change in the impedance for the compound well and the one control well, comparing the change in impedance between the compound well and the control well, and identifying the compound interacts with the RTK if the comparison demonstrates a significant difference between the change in impedance.Type: GrantFiled: August 7, 2012Date of Patent: December 23, 2014Assignee: ACEA Biosciences, Inc.Inventors: Yama A. Abassi, Naichen Yu, Josephine Atienza, Xiao Xu, Xiaobo Wang
-
Patent number: 8916340Abstract: Rational design of immunotherapeutics relies on clear knowledge of the immunodominant epitopes of antigens. Current methods for identifying kinetically stable peptide-MHC complexes are in many cases inadequate for a number of reasons. Disclosed herein is a reductionistic system incorporating known participants of MHC class II antigen processing in solution to generate peptide pools from antigens, including those for which no immunodominant epitope has yet been identified, that are highly enriched for proteolytic fragments containing their immunodominant epitopes. HLA-DM-mediated editing contributes significantly to immunodominance and is exploited in discovering immunodominant epitopes from novel or previously uncharacterized antigens, particularly antigens associated with pathogens, tumors or autoimmune diseases.Type: GrantFiled: January 8, 2007Date of Patent: December 23, 2014Assignee: The John Hopkins UniversityInventor: Scheherazade Sadegh-Nasseri
-
Publication number: 20140369939Abstract: Injectable compositions for the MRI detection of an analyte selected from the group consisting of reactive oxygen species, proteases and enzymes, comprising a) a matrix material based on a responsive hydrophobic polymer capable of undergoing a chemical reaction with the analyte to be detected, such reaction leading to a disruption of the polymer chain of the responsive polymer, b) a contrast agent suitable for use in magnetic resonance imaging, embedded in or encapsulated in the polymer a), c) optionally, a functionality capable of binding a marker or probe or a probe for creating a second detection signal, and d) optionally, a non-responsive polymer not undergoing a chemical reaction with the analyte under the conditions where polymer a) undergoes a reaction leading to chain breakageType: ApplicationFiled: June 10, 2014Publication date: December 18, 2014Inventors: V. PRASAD SHASTRI, Pradeep P. Wyss
-
Publication number: 20140370535Abstract: A sterility indicating composition comprising a plurality of sterilization process resistant spores which contain an active protease during germination and initial outgrowth of the spores; and a germination medium comprising at least one labeled protease substrate and at least one nutrient for germination of the spores; wherein the medium is essentially free of a) any active protease other than the active protease contained by the plurality of spores and b) any protease substrate other than the at least one labeled protease substrate, other than any protease substrate originating from the plurality of spores, and other than any protease substrate which does not compete with the labeled protease substrate for the active protease; and wherein the at least one labeled protease substrate comprises a peptide which can be cleaved by the active protease and which is labeled with one or more dye groups, at least one of which undergoes a detectable change when the peptide is cleaved by the active protease, and whereinType: ApplicationFiled: August 28, 2014Publication date: December 18, 2014Inventors: SAILAJA CHANDRAPATI, HEATHER M. WEBB, AI-PING WEI
-
Patent number: 8906636Abstract: The present invention relates to the field of recombinant toxin protein production in bacterial hosts. In particular, the present invention relates to production processes for obtaining high levels of a recombinant CRM197, Diphtheria Toxin, Pertussis Toxin, Tetanus Toxoid Fragment C, Cholera Toxin B, Cholera holotoxin, and Pseudomonas Exotoxin A, from a bacterial host.Type: GrantFiled: July 26, 2013Date of Patent: December 9, 2014Assignee: Pfenex Inc.Inventors: Diane M. Retallack, Lawrence Chew
-
Patent number: 8906640Abstract: The present invention provides methods for continuous measurement of protein and/or triglyceride digestibility during a meal. Stable isotope of 15N-spirulina protein and 2H5-phenylalanine was added to the nutritional supplement. Protein digestibility is calculated by measuring the ratio [15N]PHE to [2H5]PHE in plasma and the nutrition. In another embodiment, [1,1,1-13C3]tripalmitin and [2,2-2H2]palmitic acid were added to the meal. The ratio between [1-13C]palmitic acid/[2,2-2H2]palmitic acid will represent the percentage digestion of triglycerides by lipase from the pancreas.Type: GrantFiled: September 19, 2013Date of Patent: December 9, 2014Inventors: Nicolaas E Deutz, Marielle P Engelen, Gulnur Com, John J Thaden
-
Publication number: 20140357501Abstract: A peptide is cleaved at various bonding sites into oligopeptides or similar fragments by digestion using proteinase K (S3). The obtained fragments are separated according to their kinds by reversed-phase chromatography and fractionated (S4), and each fragment is subjected to mass spectrometry to determine its mass (S6). For each peptide fragment, an amino-acid composition is calculated from the measured mass, and amino-acid sequence candidates are deduced from that composition. The amino-acid sequence candidates of the other peptide fragments are searched for a fragment having an overlapping portion available for combining two peptide fragments to obtain amino-acid sequence candidates of the original peptide (S7). The masses of the amino-acid sequence candidates are compared with a measured mass derived from a result of mass spectrometry of the original peptide to select a correct sequence (S6 and S8).Type: ApplicationFiled: March 14, 2014Publication date: December 4, 2014Applicant: SHIMADZU CORPORATIONInventors: Akiyasu Yoshizawa, Takayuki Yoshimori, Yuki Ohta
-
Publication number: 20140357526Abstract: A method for analyzing the polypeptide content of animal tissue is described. The method includes the steps of (a) providing an animal tissue specimen; (b) depositing one or more portions of a hydrogel mixture including a protease on spatially discrete portions of the animal tissue specimen; (c) allowing sufficient time to pass for animal tissue under the hydrogel mixture to be form a digested mixture of animal tissue and hydrogel mixture; (d) removing the digested mixture from the animal tissue and extracting the polypeptides from the digested mixture to provide an extract; and (e) analyzing the polypeptide content of the extract by mass spectrometry.Type: ApplicationFiled: June 2, 2014Publication date: December 4, 2014Applicant: Vanderbilt UniversityInventors: Richard Caprioli, Glenn A. Harris, Joshua J. Nicklay
-
Publication number: 20140349297Abstract: The present invention relates to fluorescent dyes based on acridine and acridinium derivatives and use of such dyes in for example, biochemical and/or cell-based assays.Type: ApplicationFiled: December 20, 2012Publication date: November 27, 2014Applicant: Almac Sciences (Scotland) LimitedInventors: Beatrice Maltman, Adina-Elena Tirnaveanu, Graham Cotton
-
Publication number: 20140342383Abstract: The invention relates to novel compositions and methods for the detection of enzymes using the nuclear reorganization energy, ?, of an electron transfer process.Type: ApplicationFiled: May 19, 2014Publication date: November 20, 2014Applicant: OHMX CorporationInventors: Paul A. Bertin, Michael J. Ahrens, Dimitra Georganopoulou, Harry B. Gray, Thomas J. Meade, Markus Franz Wunder
-
Publication number: 20140341881Abstract: This invention relates to therapeutic compounds which are inhibitors of serine proteases, to pharmaceutical compositions thereof and to their use in the treatment of the human or animal body. More specifically, the present invention relates to a method for the treatment, diagnosis or prognosis of skin diseases comprising the administration to a subject in need thereof of a therapeutically effective amount of a Serine protease inhibitor.Type: ApplicationFiled: July 30, 2014Publication date: November 20, 2014Inventors: David Deperthes, Christoph Kundig, Alain Hovnanian, Celine Deraison
-
Publication number: 20140336073Abstract: A method for determining the sensitivity and/or resistance of a patient suffering from a cancer disease to Aurora kinase inhibitor therapy, which comprises determining in vitro in the cancer cells or body fluids taken from the patient the expression of at least one gene selected from a particular group and/or determining in vitro in the cancer cells or body fluids taken from the patient the level of at least one protein selected from a particular group.Type: ApplicationFiled: December 7, 2012Publication date: November 13, 2014Applicants: PALACKY UNIVERSITY, OLOMOUC, INSTITUTE OF ANIMAL PHYSIOLOGY AND GENETICS ASCR, V.V.I.Inventors: Madhusudhan Reddy Kollaredy, Marian Hajduch, Petr Dzubak, Josef Srovnal, Rita Hrabakova, Hana Kovarova
-
Patent number: 8883144Abstract: The present invention relates to agonists of Neprilysin and their use in preventing and treating pulmonary vascular remodeling. Also described are diagnostic and screening applications stemming from the inventor's discovery that Neprilysin is expressed at reduced levels in disease tissues.Type: GrantFiled: September 1, 2011Date of Patent: November 11, 2014Assignee: The Regents of the University of Colorado, a body corporateInventor: Edward C. Dempsey
-
Patent number: 8883436Abstract: Enzymes and/or polypeptides and/or mixtures of interest are evaluated during hydrolysis of cellulosic material by the use of indicator constituents such as fluorescent agents, resulting in efficient high-throughput analysis of enzymes and/or polypeptides. A high-throughput assay for the analysis of inter alia, pretreated corn stover (PCS) hydrolysis is also disclosed.Type: GrantFiled: July 13, 2010Date of Patent: November 11, 2014Assignee: Novozymes A/SInventors: Marco Malten, Keith McFarland
-
Publication number: 20140328764Abstract: The development of fluorescent bioprobes comprising organic fluorescent compounds that exhibit aggregation induced emission (AIE) properties, methods of producing the same, and their practical applications for in vitro and in vivo bioimaging.Type: ApplicationFiled: September 3, 2012Publication date: November 6, 2014Applicants: NATIONAL UNIVERSITY OF SINGAPORE, THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Benzhong Tang, Wei Qin, Jianzhao Liu, Sijie Chen, Tsz Kin Kwok, Bin Liu, Kai Li, Dan Ding, Haibin Shi, Jun Long Geng, Jingzhi Sun, Anjun Qin, Qiuli Zhao
-
Publication number: 20140328852Abstract: The invention relates to an immunogenic peptide of eight amino acids that is generated naturally in the intestine of celiac patients by means of the hydrolysis of ingested gluten. In addition, the invention relates to the use of the peptide, or antibodies generated against same, for the in vitro monitoring and/or diagnosis of celiac disease, as well as to the use of such antibodies for the detection of gluten in food. The invention further relates to the use of the aforementioned peptide as a therapeutic target for the development of compounds or compositions for use in the diagnosis, treatment and/or prevention of this pathological condition, as well as to the use of the peptide and the antibodies against same for the prevention and/or treatment of celiac disease.Type: ApplicationFiled: September 28, 2012Publication date: November 6, 2014Inventors: David Bernardo Ordiz, Jose Antonio Garrote Adrados, Alfredo Ramon Blanco Quiros, Eduardo Arranz Sanz, Angel Cebolla Ramirez
-
Patent number: 8877454Abstract: To provide an autoanalyzer for analyzing a sugar chain contained in a biological sample, in particular, serum. Namely, it is intended to provide a method of analyzing a sugar chain in a sample, which comprises the following steps: A) the sugar chain-releasing step of releasing the sugar chain in the sample; B) the detection sample-preparing step of preparing the released sugar chain for detection; and, in the case of conducting mass spectrometry using a plate, C) the step of forming a plate for the mass spectrometry having the captured sugar chain dotted thereon which comprises the step of providing the tagged sugar chain sample solution obtained in the step B) on a collection plate; and, if required, the step of conducting an operation in a solid phase support-enclosed plate to form the plate for mass spectrometry; and D) the step of analyzing the sugar chain to be assayed.Type: GrantFiled: October 3, 2008Date of Patent: November 4, 2014Assignees: National University Corporation Hokkaido University, Shionogi & Co., Ltd.Inventors: Shinichiro Nishimura, Yasuro Shinohara, Yoshiaki Miura, Hiroshi Yamazaki, Michio Horiuchi, Hiroaki Motoki, Toshiharu Kuroda, Yoko Kita, Mika Nakano
-
Publication number: 20140322740Abstract: The present invention is directed to the diagnosis of cancer associated with enzymatically active PSA in samples.Type: ApplicationFiled: March 13, 2013Publication date: October 30, 2014Applicants: NORTHWESTERN UNIVERSITY, AN ILLINOIS NOT FOR PROFIT CORPORATION, OHMX CORPORATIONInventors: OHMX CORPORATION, NORTHWESTERN UNIVERSITY, AN ILLINOIS NOT FOR PROFIT CORPORATION
-
Publication number: 20140322741Abstract: The present invention provides a low-cost cell-free assay, the ?-test, that provides point-of-care CD4 enumeration using a single platform assay thereby eliminating the need for high-end instrumentation, calibrated pipetting, and specialized technical training. The number of CD4 T cells in blood is driven by the concentration of the protein ?1 proteinase inhibitor (?1PI, ?1 antitrypsin, serpin A1). The invention features, in part, methods for determining the number of CD4+ T cells in a sample comprising determining the concentration of alpha 1 proteinase inhibitor (?1PI) in a sample; wherein the number of CD4+ T-cells is related to the concentration of ?1PI.Type: ApplicationFiled: July 8, 2014Publication date: October 30, 2014Inventor: Cynthia L. Bristow
-
Patent number: 8871460Abstract: In accordance with the present invention, it has been discovered that compounds which modulate the ?-secretase enzyme to make more of the shorter, less toxic and less aggregation-prone A? peptides (such as A?37 and A?38), while making less of the longer and more toxic and aggregation-prone AB peptides (such as AB40 and AB42) are useful as gamma-secretase modulators. In addition, these GSM compounds have further been discovered to have the selective property of modulating the formation of various AB peptides, while not inhibiting the overall activity of the ?-secretase enzyme. Thus, such compounds do not impede other critical functions of the ?-secretase enzyme, such as generating fragments from Notch that appear to control gene expression and cell differentiation. Therefore, in accordance with the present invention, there are provided screening assays useful for determining whether test compounds have GSM activity; accordingly, invention assays facilitate the identification of new gamma-secretase modulators.Type: GrantFiled: November 8, 2010Date of Patent: October 28, 2014Assignee: Neurogenetic Pharmaceuticals, Inc.Inventors: Maria Z. Kounnas, Elizabeth J. Ackermann, Kenneth A. Stauderman, Gonul Velicelebi, Steve Wagner
-
Patent number: 8871688Abstract: The present invention relates to a method for absolute quantification of polypeptides.Type: GrantFiled: June 2, 2008Date of Patent: October 28, 2014Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Commissariat a l'Energie AtomiqueInventors: Virginie Brun, Alain Dupuis, Jerome Garin
-
Patent number: 8871459Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Beta-2-glycoprotein 1 as a diagnostic and prognostic biomarker in renal injuries.Type: GrantFiled: August 6, 2010Date of Patent: October 28, 2014Assignee: Astute Medical, Inc.Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura